公开(公告)号：US20180185314A1

公开(公告)日：2018-07-05

申请号：US15908571

申请日：2018-02-28

申请人： The Children's Medical Center Corporation ,  The General Hospital Corporation

发明人： Umut Ozcan ,  Joseph Majzoub ,  Ralph Mazitschek ,  Isin Cakir ,  Serkan Cabi

IPC分类号： A61K31/198 ,  A61K45/06 ,  A61K31/19 ,  A61K38/22 ,  A61K31/192 ,  A61K31/194 ,  A61K31/195

CPC分类号： A61K31/198 ,  A61K31/19 ,  A61K31/192 ,  A61K31/194 ,  A61K31/195 ,  A61K38/2264 ,  A61K45/06 ,  A61P3/04 ,  A61K2300/00

摘要： Pentacyclic triterpene weight loss agents are provided herein. Also provided are pharmaceutical formulations containing a therapeutically effective amount of one or more of the weight loss agents, or pharmaceutically acceptable salts or prodrugs thereof, in combination with one or more pharmaceutically acceptable excipients. The pharmaceutical formulations can be administered to a pre-obese, obese, or morbidly obese patient to induce weight loss, reduce body fat, reduce food intake, improve glucose homeostasis, prevent obesity, or a combination thereof. The weight loss agents can also be co-administered with leptin or a leptin analog.

公开(公告)号：US09968575B2

公开(公告)日：2018-05-15

申请号：US14431412

申请日：2013-09-26

申请人： The Children's Medical Center Corporation ,  The General Hospital Corporation

发明人： Umut Ozcan ,  Joseph Majzoub ,  Ralph Mazitschek ,  Isin Cakir ,  Serkan Cabi

IPC分类号： C07C62/38 ,  A61K31/198 ,  A61K31/192 ,  A61K31/194 ,  A61K31/195 ,  A61K38/22 ,  A61K31/19 ,  A61K45/06

CPC分类号： A61K31/198 ,  A61K31/19 ,  A61K31/192 ,  A61K31/194 ,  A61K31/195 ,  A61K38/2264 ,  A61K45/06 ,  A61K2300/00

摘要： Pentacyclic triterpene weight loss agents are provided herein. Also provided are pharmaceutical formulations containing a therapeutically effective amount of one or more of the weight loss agents, or pharmaceutically acceptable salts or prodrugs thereof, in combination with one or more pharmaceutically acceptable excipients. The pharmaceutical formulations can be administered to a pre-obese, obese, or morbidly obese patient to induce weight loss, reduce body fat, reduce food intake, improve glucose homeostasis, prevent obesity, or a combination thereof. The weight loss agents can also be co-administered with leptin or a leptin analog.

公开(公告)号：US20170304245A1

公开(公告)日：2017-10-26

申请号：US15644247

申请日：2017-07-07

申请人： The Children's Medical Center Corporation ,  The General Hospital Corporation

发明人： Umut Ozcan ,  Joseph Majzoub ,  Ralph Mazitschek ,  Isin Cakir ,  Serkan Cabi

IPC分类号： A61K31/198 ,  A61K38/22 ,  A61K31/195 ,  A61K31/194 ,  A61K31/192 ,  A61K45/06 ,  A61K31/19

CPC分类号： A61K31/198 ,  A61K31/19 ,  A61K31/192 ,  A61K31/194 ,  A61K31/195 ,  A61K38/2264 ,  A61K45/06 ,  A61K2300/00

摘要： Pentacyclic triterpene weight loss agents are provided herein. Also provided are pharmaceutical formulations containing a therapeutically effective amount of one or more of the weight loss agents, or pharmaceutically acceptable salts or prodrugs thereof, in combination with one or more pharmaceutically acceptable excipients. The pharmaceutical formulations can be administered to a pre-obese, obese, or morbidly obese patient to induce weight loss, reduce body fat, reduce food intake, improve glucose homeostasis, prevent obesity, or a combination thereof. The weight loss agents can also be co-administered with leptin or a leptin analog.

公开(公告)号：US09925161B2

公开(公告)日：2018-03-27

申请号：US15644247

申请日：2017-07-07

申请人： The Children's Medical Center Corporation ,  The General Hospital Corporation

发明人： Umut Ozcan ,  Joseph Majzoub ,  Ralph Mazitschek ,  Isin Cakir ,  Serkan Cabi

IPC分类号： A61K31/198 ,  A61K31/19 ,  A61K31/192 ,  A61K38/22 ,  A61K45/06 ,  A61K31/194 ,  A61K31/195

CPC分类号： A61K31/198 ,  A61K31/19 ,  A61K31/192 ,  A61K31/194 ,  A61K31/195 ,  A61K38/2264 ,  A61K45/06 ,  A61K2300/00

摘要： Pentacyclic triterpene weight loss agents are provided herein. Also provided are pharmaceutical formulations containing a therapeutically effective amount of one or more of the weight loss agents, or pharmaceutically acceptable salts or prodrugs thereof, in combination with one or more pharmaceutically acceptable excipients. The pharmaceutical formulations can be administered to a pre-obese, obese, or morbidly obese patient to induce weight loss, reduce body fat, reduce food intake, improve glucose homeostasis, prevent obesity, or a combination thereof. The weight loss agents can also be co-administered with leptin or a leptin analog.

公开(公告)号：US20170209408A1

公开(公告)日：2017-07-27

申请号：US15301475

申请日：2015-04-03

申请人： The Children's Medical Center Corporation

发明人： Umut Özcan ,  Isin Cakir ,  Serkan Cabi

IPC分类号： A61K31/352 ,  A61K31/5377 ,  A61K31/395

CPC分类号： A61K31/352 ,  A61K31/395 ,  A61K31/5377

摘要： HSP 90 inhibitors for the promotion of weight loss, as well as formulations containing these inhibitors and methods of using thereof, are described herein. Also provided are pharmaceutical compositions containing a therapeutically effective amount of a weight loss agent, or a pharmaceutically acceptable salt or prodrug thereof, in combination with one or more pharmaceutically acceptable excipients. The pharmaceutical compositions can be administered to induce weight loss in a pre-obese, obese, or morbidly obese patient, reduce body fat in a pre-obese, obese, or morbidly obese patient, reduce food intake in a pre-obese, obese, or morbidly obese patient, improve glucose homeostasis in a pre-obese, obese, or morbidly obese patient, or combinations thereof. In particular embodiments, the weight loss agent is co-administered with leptin or a leptin analog.

公开(公告)号：US20150250753A1

公开(公告)日：2015-09-10

申请号：US14431412

申请日：2013-09-26

申请人： THE CHILDREN'S MEDICAL CENTER CORPORATION ,  THE MASSACHUSETTS GENERAL HOSPITAL

发明人： Umut Ozcan ,  Joseph Majzoub ,  Ralph Mazitschek ,  Isin Cakir ,  Serkan Cabi

IPC分类号： A61K31/198 ,  A61K31/19 ,  A61K38/22 ,  A61K31/195 ,  A61K31/194 ,  A61K45/06 ,  A61K31/192

CPC分类号： A61K31/198 ,  A61K31/19 ,  A61K31/192 ,  A61K31/194 ,  A61K31/195 ,  A61K38/2264 ,  A61K45/06 ,  A61K2300/00

摘要： Pentacyclic triterpene weight loss agents are provided herein. Also provided are pharmaceutical formulations containing a therapeutically effective amount of one or more of the weight loss agents, or pharmaceutically acceptable salts or prodrugs thereof, in combination with one or more pharmaceutically acceptable excipients. The pharmaceutical formulations can be administered to a pre-obese, obese, or morbidly obese patient to induce weight loss, reduce body fat, reduce food intake, improve glucose homeostasis, prevent obesity, or a combination thereof. The weight loss agents can also be co-administered with leptin or a leptin analog.

摘要翻译： 本文提供五环三萜减肥剂。 还提供了含有治疗有效量的一种或多种减肥剂或其药学上可接受的盐或前药与一种或多种药学上可接受的赋形剂组合的药物制剂。 药物制剂可以施用于肥胖前，肥胖或病态肥胖的患者，以诱导体重减轻，减少体脂肪，减少食物摄入，改善葡萄糖体内平衡，预防肥胖或其组合。 减肥剂也可以与瘦素或瘦蛋白类似物共同施用。